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Irritable bowel syndrome (IBS) is a disorder associated with muscarinic receptors
(M3) and characterized by cramping, abdominal pain, bloating, constipation and/or di-
arrhea (1, 2). Pain and intestinal spasms are the common state in chronic colon condi-
tions such as irritable bowel syndrome, diverticulitis, and colitis. The muscarinic anta-
gonistic activities, mediated by M3 receptors, are responsible for the smooth muscle
spasm (3, 4). Antispasmodics are the most commonly used drugs, of which antimuscari-
nic agents are an important class. However, the efficacy of these agents is significantly
limited due to lack of receptor subtype selectivity, resulting in unacceptable atropine-
-like side effects.
M3-selective antimuscarinic agents were sucessfully used in the treatment of IBS
with minimal atropine-like side effects (5).
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A series of 1-substituted imidazoles 1a-d and 2a-d were
synthesized and screened for antispasmodic and antidiar-
rheal activities. Antispasmodic activity was tested at vari-
ous concentrations on isolated tissue preparations; con-
centration-response curves were plotted and compared
with atropine. All compounds were found to inhibit con-
traction of the guinea pig ileum. Castor oil-induced diar-
rhea model in rats was used for evaluation of antidiar-
rheal activity. Parameters such as intestinal transit and vol-
ume of intestinal fluid were measured for antidiarrheal
activity at 40 mg kg–1 dose and compared with the stan-
dard drug loperamide at 6 mg kg–1 dose. Defecation fre-
quency in the test group was found to be significantly
lower (p < 0.01) compared to the control group and com-
parable with that of the standard. The present study re-
veals that the compounds exert antidiarrheal activity
through possible inhibition of intestinal movement and
reduction of capillary permeability in the abdominal
cavity.
Keywords: 1-substituted imidazoles, antispasmodic, anti-
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Imidazole nucleus has been proven to have a number of medicinal properties (anti-
protozoal, mutagenic, anticancer, antiviral, enzyme inhibition, H2-antagonism, a-adre-
nergic agonism and b-blocking, anticonvulsant, antibacterial and antifungal) and has been
also reported to have antimuscarinic activity (6). Against this background, the present
study explores the possibility of imidazoles as M3-selective antagonists.
A series of 1-substituted imidazoles were synthesized and evaluated for their anti-
spasmodic activity on isolated guinea pig ileum and antidiarrheal activity on castor oil-
-induced diarrhea on a rat model, respectively. As a result, these 1-substituted imida-
zoles might possibly lead to the development of compounds with probable muscarinic
(M3) antagonistic activity, especially to relieve pain in smooth muscles in conditions such
as diarrhea and gastrointestinal disorders.
EXPERIMENTAL
Melting points were determined in open glass capillaries using an Electro thermal
IA 9000 SERIES digital melting point apparatus (Electrothermal, UK) and are uncorrec-
ted. FT-IR spectra were taken on an IR-Prestige 21 (Shimadzu, Japan) from 4000–400 cm–1
using potassium bromide discs. 1H NMR spectra were recorded at 300 MHz on a Bruker
DRX-300 instrument (Bruker Instruments Inc., USA) using CDCl3 as solvent (7). Chemi-
cal shifts were measured at d units (ppm) relative to tetramethylsilane (TMS). Mass spec-
tra were taken on a JEOL AccuTOF-DART mass spectrometer (Japan). Elemental analy-
ses were performed on a Vario EL III Elemental Analyser (Elementar, Germany) using
sulfanilamide as standard. In the elemental analysis, the observed values were within ±
0.4 % of the calculated values. The purity of all compounds was established by a single
spot on TLC plates (Merck, Germany). Iodine vapors were used as the developing agent
and the solvent system used for the TLC analysis was benzene and ethanol (8:2). Imi-
dazole, 2-methyl imidazole and para-substituted phenacyl bromides were procured from
Sigma-Aldrich, USA. Acetylcholine hydrochloride (Hi-media, India), atropine sulfate
(Hi-media) and loperamide hydrochloride (Torrent, India), and all other chemicals used
in the study were of analytical grade.
The synthetic pathways for compounds 1a-d and 2a-d are given in Scheme 1 (8, 9).
Synthesis of 1-(4-substituted-phenyl)-2-(2-methyl-1H-imidazol-1-yl)ethanone (1a-d) and
1-(4-substituted phenyl)-2-(1H-imidazol-1-yl) ethanone (2a-d). – To a solution of imida-
zole/2-methylimidazole (0.03 mol, 2.46 g/0.03 mol, 2.04 g) in dry DMF (10 mL) a solu-
tion of appropriate para-substituted phenacyl bromide (0.002 mol, 0.46 g) in 10 mL of dry
DMF was added dropwise at a temperature of 5–10 °C, with stirring. The stirring was
continued for another 3–6 h at the same temperature. Then the mixture was poured into
cold water (20 mL) and stirred for another hour. The precipitate obtained was removed
by filtration and the filtrate was extracted with benzene. Upon evaporation of organic
layer, compounds 1a-d and 2a-d were obtained as a crystalline mass and were recrys-
tallized from benzene/ethanol (8, 9).
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Pharmacological evaluation
Isolated tissue preparation. – Male albino guinea pigs (weighing 370–450 g) were kept
fasting for 18 h prior to commencement of the experiment and were given water ad libi-
tum. They were then sacrificed by a blow on the head and exsanguinated as per CPCSEA
recommended guidelines with the Institutional Animal Ethics Committee (Birla Institute
of Technology, Mesra, Ranchi, India) approval for animal experimentation. The caecum
was lifted and the ileocaecal junction was identified (10). The ileum was cut at this point
and transferred to a dish containing tyrode solution (11). A terminal segment of ileum of
about 1–1.5 cm was cut, and intestinal contents were removed and freed from mesen-
teric attachments. A thread was tied at each end of the tissue taking care that ileum was
left open and the thread did not close the lumen (12). The tissue was mounted into a
30-mL organ bath filled with tyrode solution. The temperature was maintained at 37 °C
and oxygenated with a mixture of 95 % O2 and 5 % CO2 continuously. Initial tension
was 1 g and stabilization time was 45–60 min. Load was adjusted to 0.5 g and a bath vol-
ume of about 15 mL was maintained. The preparation was washed every 10 min with
tyrode solution. After an initial equilibration period of about 30–45 min, increasing con-
centrations of acetylcholine hydrochloride (0.1, 0.2, 0.4, 0.8, 1.6, 3.2 mL of 10 mg mL–1)
were added to the bath and the concentration-response curve was recorded as a control
with a contact time of 90 seconds. The height from the baseline was expressed as percent
of the maximum response of acetylcholine (13).
Antispasmodic activity. – Antispasmodic (anticholinergic) effects of the test compo-
unds (1a-d, 2a-d) were tested in guinea pig ileum prepared as described earlier. All the
test compounds were suspended in aqueous Tween 80 (2 %, V/V) and the standard drug
was dissolved in distilled water. Test drugs were studied at various concentrations (10,
50 and 100 mg mL–1) and atropine sulfate at 10 mg mL–1. A test drug or standard was
added to the bath 5 min before the administration of acetylcholine hydrochloride. The
ability of the test drug to antagonize acetylcholine induced contractions was recorded as
changes in height with respect to the control. The concentration-response curve was con-
structed until the ceiling effect was obtained. Six graded-response curves were obtained
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for each preparation, with a 20-min rest between each (14). The mean maximal response
obtained from the first concentration-response curve (in the absence of lead compounds)
was taken as the 100 % response value (15). After completing the concentration-response
curve, contractions were recorded using the frontal writing lever on kymograph. The kymo-
gram was fixed with a fixing solution containing shellac and colophony in alcohol (14, 15).
Castor oil-induced diarrhea. – Male Wistar rats were screened initially by giving 1 mL
of castor oil and only those showing diarrhea were selected and grouped for the final ex-
periment. Each rat was randomly placed in an individual cage, the floor of which was
lined with blotting paper. The floor lining was changed every hour. The animals were
divided into their respective groups of six animals each. Each rat received 2 mL of castor
oil orally 30 min before commencement of the experiment. All rats were orally treated
with vehicle (aqueous Tween 80, 2 %, V/V, 10 mL kg–1 bm), test compounds (1a-d and
2a-d, 40 mg kg–1 bm) and standard drug (loperamide, 6 mg kg–1 bm). After administra-
tion of the test drug/standard drug the animals were observed for a period of 6 h. The
number of diarrheic feces excreted by the animals (recorded as scores) and the cumula-
tive mass of fecal matter collected over a period of 6 h were recorded. The changes in
body mass between the pre- and post-experiment were also determined. The percent in-
hibition of defecation score and fecal mass was calculated (16, 17).
Intestinal transit and intestinal fluid. – Each rat in the experimental group was orally
administered 2 mL of castor oil as described earlier in the castor oil-induced diarrhea
method (15, 16). The rats were also given 10 % activated charcoal in physiological saline
in a volume of 3 mL kg–1, 30 min after being given compounds 1a-d and 2a-d (40 mg
kg–1) and loperamide (6 mg kg–1). Intestinal transit and the volume of intestinal fluid in
rats were measured (18). The rats were anesthetized 15 min later by inhalation of ether
and euthanized by cervical dislocation. The small intestine from the pylorus to the cae-
cum was dissected. The individual distance travelled by the charcoal in centimetres di-
vided by the total length of the intestines in centimetres (pylorus to caecum) was calcu-
lated for each rat and expressed as percentage. Intestinal fluid accumulation was deter-
mined by castor oil-induced enteropooling method. Intestinal contents were collected into
a graduated tube and their volume was measured (19).
Statistical analysis
Results were expressed as mean ± SEM. Statistical significance was determined by
the one-way analysis of variance (ANOVA) followed by Dunnett’s test.
RESULTS AND DISCUSSION
Chemistry
Formation of compounds 1a-d and 2a-d was confirmed by the presence of charac-
teristic bands for C–N stretching at 3400–3100 cm–1 and C=O stretch at 1610–1680 cm–1
in the IR spectrum. Compound 1a, as a representative of imidazoles, showed m/z 235
(M+1)+ and compound 2a, which represented 2-methylimidazoles, showed m/z 221
(M+1)+. 1H NMR spectra of 1a-d displayed a singlet for methyl protons at 2.309–2.336
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ppm. Protons of methylene group appeared at 5.266–5.348 ppm as singlets. Protons of
imidazole displayed a doublet at 7.71–8.10 ppm, and aromatic protons of phenyl group
displayed a multiplet at 6.80–7.50 ppm. Elemental analysis data together with 1H NMR
data supported the proposed structure for compounds 1a-d and 2a-d (Tables I and II).
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1a Cl C12H11ClN2O 234.68 55 149–152 61.41/ 61.38 4.72/4.66 11.94/11.86
1b Br C12H11BrN2O 279.13 41 186–188 51.63/51.49 3.97/3.87 10.04/09.94
1c C6H5 C18H16N2O 276.33 58 182–185 78.24/78.13 5.84/5.76 10.14/10.11
1d NO2 C12H11N3O3 245.23 64 194–196 58.77/58.59 4.52/4.42 17.13/17.09
2a Cl C11H9ClN2O 220.65 52 132–135 61.41/61.39 4.72/4.67 11.94/11.83
2b Br C11H9BrN2O 265.10 59 142–144 49.84/49.79 3.42/3.35 10.57/10.43
2c C6H5 C17H14N2O 262.30 66 164–166 77.84/ 77.76 5.38/5.25 10.68/10.56
2d NO2 C11H9N3O3 231.20 62 152–154 57.14/57.11 3.92/3.79 18.17/18.03
Table II. Spectral data of synthesized compounds
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7–7.4 (m, 4H, Ar-H), 7.5 (d, 1H, Het-H)
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2.34 (s, 3H, -CH3), 5.34 (s, 2H, CH2),
7.2–7.5 (m, 4H, Ar-H), 7.6 (d, 1H, Het-H),





5.37 (s, 2H, -CH2), 6.9–7.4 (m, 4H, Ar-H),





5.364 (s, 2H, -CH2), 6.9–7.4 (m, 4H, Ar-H), 7.7





5.43 (s, 2H, -CH2), 7.3–7.5 (m, 9H, Ar-H),
7.6 (d, 1H, Het-H), 7.7 (d, 1H, Het-H),





5.66 (2H, s, -CH2), 7.3–7.5 (m, 4H, Ar-H),
7.6 (d, 1H, Het-H), 8.2 (d, 1H, Het-H),
8.3 (s, 1H, Het-H)
232 (M+H)+
Antispasmodic activity
Antagonistic activity of the compounds 1a-d and 2a-d was tested at various concen-
trations (10, 50 and 100 mg mL–1), and concentration-response curves were plotted to check
the antagonistic activity of the compounds against acetylcholine (13). All the compounds
at 100 mg mL–1 significantly (p < 0.05) antagonized the contraction of guinea pig ileum,
in a competitive and concentration-dependent manner. This is manifested by plotting
pM values (4.78–6.26); a logarithmic conversion of the number of moles of acetylcholine
present in the organ bath) against % maximal response as shown in Fig. 1. (14).
All compounds were found to produce a competitive antagonistic action against
acetylcholine at all three concentrations, which is probably mediated through muscari-
nic receptors present in the smooth muscle (M3). The chloro- and nitro-substituted phe-
nacyl imidazoles showed significant (p < 0.05) antagonistic action only at 100 mg mL–1,
whereas the bromo- and phenyl-substituted phenacyl imidazoles were found to be more
effective in their antagonistic action at 50 mg mL–1 compared to the chloro- and nitro-
-substituted compounds.
Antidiarrheal activity
Antidiarrheal activity of compounds 1a-d and 2a-d was tested at a concentration of
40 mg kg–1 bm against loperamide at 6 mg kg–1 bm. The results of antidiarrheal study
clearly showed that all compounds reduced the severity of diarrhea and fecal mass in-
duced by castor oil. Compounds 1a, 1d and 2a showed significant (p < 0.01) inhibition
against the control, whereas compounds 1b, 1c, 2b, 2c and 2d showed comparable activ-
ity with that of the standard loperamide.
In intestinal transit and intestinal fluid accumulation, compounds 1b, 2c and 2d pro-
duced significant inhibition (p < 0.01) against the control at 40 mg kg–1 bm. Compounds
1a, 1c, 1d and 2a produced significant (p < 0.05) inhibition against the control. Amongst
all, compound 2b showed marked inhibition (p < 0.001), which was comparable with
loperamide.
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50 g mLm –1 50 g mLm –1
atropine atropine
10 g mLm –1 10 g mLm –1
10 g mLm –1 10 g mLm –1
Fig. 1. The contractile response elicited by acetylcholine on guinea pig ileum in the presence and in the
absence of atropine and compounds: a) 1a and b) 1b. pM: –log n (acetylcholine) (mean ± S.E.M,
n = 6) in the organe bath.
Since 1-substituted imidazoles successfully inhibited the castor oil-induced diarrhea,
it can be assumed that the antidiarrheal action was mediated by an antisecretory mecha-
nism (18) and also decreased the intestinal muscle tone and peristalsis of the gastro-in-
testinal tract by slowing the movement of fecal matter through the gastro-intestinal tract.
This was also evident from the reduction of the total number of copious feces in test
groups.
Structure activity relation
All the compounds exhibited dose-dependent antispasmodic activity, as evident from
the maximal response percentage (Fig. 1). Imidazole derivatives without methyl substi-
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% transit
% reduction
Fig. 2. Effect of compounds 1a-d and 2a-d (40 mg kg–1) and loperamide (6 mg kg–1) on intestinal
transit and reduction in the castor oil-induced diarrhea in rats.
Table III. Effect of test compounds (40 mg kg–1) and loperamide (6 mg kg–1) on castor
oil-induced diarrhea in rats
Treatment Total score (inhibition, %) Fecal mass (inhibition, %) Change in body mass (%)
Control 0 0 1.1 ± 0.2
1a 59.1c 53.5c 0.7 ± 0.2
1b 76.0d 74.0d 0.3 ± 0.1
1c 72.3d 69.8d 0.4 ± 0.2
1d 58.0c 57.0c 0.4 ± 0.1
2a 65.1c 65.2c 0.5 ± 0.2
2b 83.1d 82.0d 0.3 ± 0.1
2c 81.0d 78.3d 0.3 ± 0.1
2d 77.1c 77.0d 0.4 ± 0.1
Loperamide 98.0d 97.0d 0.1 ± 0.1
a Test compounds: 40 mg kg–1 bm, loperamide (6 mg kg–1 bm).
b Values are mean ± SEM, n = 6.
c Significantly different from loperamide (p < 0.05).
d Significantly different from the control (p < 0.01).
tution at the 2nd position (2a-d) have shown better antispasmodic activity. The same ap-
plies to antidiarrheal activity. Amongst the four electron withdrawing groups as substi-
tuents studied at para position of phenyl ring (chloro, bromo, phenyl and nitro), the bro-
mo derivatives (2b and 1b) have shown the highest antidiarrheal activity. The antidiar-
rheal activity profile can be summarized as: 2b > 1b > 2c > 2d > 1c > 1d > 2a > 1a and is
evident from the percentage inhibition (Table III).
CONCLUSIONS
It is evident from the present findings that the synthesized 1-substituted imidazoles
1a-d and 2a-d showed marked muscarinic anticholinergic activity in isolated guinea pig
ileum. In this work, the 1-substituted imidazoles were found to possess relaxant activity
on the guinea pig ileum smooth muscle spasm produced by acetylcholine and to inhibit
the castor oil-induced diarrhoea in rats with a significant antidiarrheal effect. These fin-
dings could be utilized to design compounds with superior activity in promoting anti-
diarrheal effect in conditions like cramping, abdominal pain, bloating, constipation and
diarrhea.
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S A @ E T A K
Sinteza, spazmolitsko i antidijaretsko djelovanje nekih 1-supstituiranih
derivata imidazola
BASKAR LAKSHMANAN, PAPIYA MITRA MAZUMDER, DINAKAR SASMAL i SWASTIKA GANGULY
U radu je opisana sinteza serije novih 1-supstituiranih imidazola 1a-d i 2a-d te eva-
luacija njihovog spazmolitskog i antidijaretskog djelovanja. Spazmolitsko djelovanje raz-
li~ith koncentracija ispitivanih spojeva (10, 50 i 100 mg mL–1) ispitano je na izoliranim
tkivnim preparatima; krivulje ovisnosti djelovanja o koncentraciji uspore|ene su s djelo-
vanjem atropina. Svi ispitivani spojevi inhibirali su kontrakcije ileuma zamorca. Dijarea
inducirana ricinusovim uljem u {takora kori{tena je za vrednovanje antidijaretskog
djelovanja. Intestinalni prijenos i volumen intestinalne teku}ine mjereni su pri dozi
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od 40 mg kg–1 i uspore|eni s u~inkom standarda loperamida (doza 6 mg kg–1). U~es-
talost defekacije u testiranoj skupini bila je zna~ajno ni`a (p < 0,01) u usporedbi s kon-
trolnom skupinom i standardom. Provedena ispitivanja pokazuju da antidijaretsko dje-
lovanje ispitivanih spojeva mo`e biti posljedica inhibicije intestinalnih pokreta i reduk-
cije kapilarne permeabilnosti u abdominalnoj {upljini.
Klju~ne rije~i: 1-supstituirani imidazoli, spazmolitik, antidijaretik, gastrointestinalni prijenos
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